Vir’s George Scangos, Westlake Village BioPartners’ Sean Harper, Kronos Bio’s Norbert Bischofberger, Scorpion’s Axel Hoos and Eikon’s Roy Baynes discuss the experiences they bring and the challenges they have faced in the transition from large drug makers to small biotechs. 

Emerging from stealth mode, the Californian biotech aims to tackle aging processes looks to have some things in common with multi-billion dollar start up Altos.while also looking to legitimize the science of blood plasma transfusions.

At a recent healthcare forum in Seoul, South Korea regenerative medicine industry executives and researchers discussed the current status of the sector, as well as what policy changes and support are needed to invigorate research, development and commercialization. 

Research chief Barron is departing before his turnaround of GSK is fully realized but the consumer division spin-out could unlock new R&D money to help it challenge the sector’s leaders.